Beyond 700 Pty Ltd
Beyond 700 is a privately-owned company based in Sydney, Australia.
Over 95% of the Beyond 700 shares are held by the founders and current directors.
The Company will be raising its first external funding round (Series A) in 2024.
TearView Product Status
The TearView® camera uses a patented method that senses the photon emittance and allows visualization of the tear film utilising an ultra low-noise 2D sensor array and lens system. TearView® is a ‘point and record’ camera allowing the complete exam of both eyes in less than 2 minutes. The output is a 10-30 second video of the tear film function for each eye.
The 3rd generation of the TearView system is now completed, including the TearView imaging software system
Tear View Regulatory Status
Australia
TearView® product is approved by the TGA in Australia/NZ as a Class I medical device.
USA
In the USA the FDA 510k application has been filed and currently the reviewer’s queries are being answered.
Europe
The TearView CE Mark Class I application is being finalised for submission 1st Half 2024
Other Jurisdictions
Opportunities for TearView sales in ‘early access’ markets with simpler regulatory/registration processes for such products are being explored, based on have ‘home market” Australia TGA approval for Tear View.
Intellectual Property
Two patent families protect TearView and are filed in the major markets (USA, EU, Japan, China) and the ‘TearView’ name is trademarked in these countries.